Tonix Pharmaceuticals partners with USAMMDA to examine TNX-102 SL for post-traumatic stress disorder in warfighters.
M2 EQUITYBITES-December 8, 2015-Tonix Pharmaceuticals partners with USAMMDA to examine TNX-102 SL for post-traumatic stress disorder in warfighters
(C)2015 M2 COMMUNICATIONS http://www.m2.com
Medicine company Tonix Pharmaceuticals Holding (NASDAQ:TNXP) disclosed on Monday the launch of a Cooperative Research and Development Agreement (CRADA) to explore expansion and potential development of its investigational new drug, TNX-102 SL, for treating military-related post-traumatic stress disorder (PTSD).
The company has signed the agreement with the US Army Medical Materiel Development Activity (USAMMDA)
USAMMDA is the Department of Defense's (DoD) advanced development activity for products designed to protect and preserve the lives of Warfighters. USAMMDA develops new drugs, vaccines and medical support equipment that enhance readiness, and ensures the provision of the highest quality medical care to the DoD.
TNX-102 SL (cyclobenzaprine HCl sublingual tablets) is a small, rapidly dissolving tablet containing very low dose cyclobenzaprine in a eutectic formulation for sublingual (under the tongue) administration and rapid absorption into the blood stream. It is designed for use at bedtime to improve sleep quality and to have a tolerability profile that supports chronic treatment, concluded Tonix.
((Comments on this story may be sent to firstname.lastname@example.org))
|Printer friendly Cite/link Email Feedback|
|Publication:||M2 EquityBites (EQB)|
|Date:||Dec 8, 2015|
|Previous Article:||Sucampo buys R-Tech Ueno for USD275m.|
|Next Article:||Comtech Telecommunications announces commencement of tender offer for TeleCommunication Systems.|